Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN RUBINO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1962543280
CMS profile
43312
Location
RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$543.04

31 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $543.04 31

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN RUBINO

NPI 1962543280 · CMS profile ID 43312

Allopathic & Osteopathic Physicians / Internal Medicine

RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962543280?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962543280?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962543280?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOHN RUBINO, NPI 1962543280, CMS profile ID 43312, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1962543280?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

31 matching records · $543.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 31 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–31 of 31.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Horizon Therapeutics plc $16.5212/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937684455 CMS
Lilly USA, LLC $18.3611/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918098477 CMS
Teva Pharmaceuticals USA, Inc. $15.3510/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954621585 CMS
OptiNose US, Inc. $23.3910/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928119391 CMS
AstraZeneca Pharmaceuticals LP $19.4610/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915518235 CMS
Sunovion Pharmaceuticals Inc. $24.8610/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920953597 CMS
Merck Sharp & Dohme LLC $13.0109/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944235687 CMS
PFIZER INC. $16.7709/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949311707 CMS
SANOFI-AVENTIS U.S. LLC $16.9908/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938743617 CMS
ABBVIE INC. $24.3008/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891489539 CMS
Novo Nordisk Inc $16.6208/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898800579 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.4707/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887400393 CMS
Novo Nordisk Inc $15.3007/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898898965 CMS
Amgen Inc. $12.9507/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940055465 CMS
GlaxoSmithKline, LLC. $22.1307/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944344485 CMS
Lilly USA, LLC $11.7906/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918095145 CMS
ABBVIE INC. $13.4106/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891489537 CMS
Novartis Pharmaceuticals Corporation $12.8506/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894304157 CMS
Novo Nordisk Inc $24.1605/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898800585 CMS
Novartis Pharmaceuticals Corporation $16.9205/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894304153 CMS
Merck Sharp & Dohme LLC $12.9305/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944152885 CMS
E.R. Squibb & Sons, L.L.C. $16.8004/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932626673 CMS
Amgen Inc. $13.5204/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939809907 CMS
Novo Nordisk Inc $20.5703/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898622349 CMS
ABBVIE INC. $15.6103/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891489535 CMS
Novo Nordisk Inc $16.0402/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898549937 CMS
PFIZER INC. $21.4202/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949093417 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.6702/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955803619 CMS
AstraZeneca Pharmaceuticals LP $11.9401/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914982131 CMS
Teva Pharmaceuticals USA, Inc. $16.6201/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954621143 CMS
Novo Nordisk Inc $24.3101/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898800593 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,823.22 39
PY2020 $410.97 28
PY2021 $698.79 47
PY2022 $543.04 31
PY2023 $6,389.49 35
PY2024 $1,915.52 44
PY2025 $1,251.65 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,783,192.12 359
PY2024 Recipient $66,231.01 15
PY2024 Principal investigator $2,510,578.54 317
PY2023 Recipient $6,417.61 4
PY2023 Principal investigator $2,159,960.11 267
PY2022 Principal investigator $2,441,546.83 286
PY2021 Principal investigator $1,166,336.49 169
PY2020 Principal investigator $1,326,147.90 192
PY2019 Principal investigator $636,986.48 193

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

169 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $9,676.83 12/31/2021 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 848762433
Principal investigator 1 Janssen Pharmaceuticals, Inc $79,712.00 12/28/2021 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787568559
Principal investigator 1 PFIZER INC. $827.66 12/28/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832558655
Principal investigator 1 PFIZER INC. $517.05 12/22/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF VUPANORSEN PF07285557 IN STATINTREATED PARTICIPANTS WITH DYSLIPIDEMIA No dispute reported 06/30/2026 832559023
Principal investigator 1 PFIZER INC. $4,718.25 12/22/2021 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832559031
Principal investigator 1 PFIZER INC. $1,512.00 12/22/2021 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832564883
Principal investigator 1 Kowa Research Institute, Inc. $1,046.70 12/21/2021 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 771715116
Principal investigator 1 Becton, Dickinson and Company $15,145.50 12/16/2021 Non-covered Recipient Entity
ACCELLACARE US INC
SUST030 No dispute reported 06/30/2026 840548993
Principal investigator 1 Kowa Research Institute, Inc. $1,993.50 12/14/2021 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 771715114
Principal investigator 1 PFIZER INC. $1,080.00 12/07/2021 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832558663
Principal investigator 1 PFIZER INC. $1,911.60 12/07/2021 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832558672
Principal investigator 1 PFIZER INC. $413.83 12/07/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832559457
Principal investigator 1 Kowa Research Institute, Inc. $946.80 12/01/2021 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 771715112
Principal investigator 1 PFIZER INC. $413.83 12/01/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832559013
Principal investigator 1 PFIZER INC. $52,478.55 11/23/2021 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832654693
Principal investigator 1 PFIZER INC. $2,093.85 11/23/2021 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832726421
Principal investigator 1 PFIZER INC. $1,884.00 11/23/2021 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 832730915
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,767.00 11/22/2021 Non-covered Recipient Entity
PMG RESEARCH INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851030269
Principal investigator 1 Janssen Pharmaceuticals, Inc $36,726.00 11/22/2021 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787568531
Principal investigator 1 PFIZER INC. $827.66 11/18/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832599673
Principal investigator 1 PFIZER INC. $1,827.90 11/05/2021 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832787681
Principal investigator 1 PFIZER INC. $517.05 11/05/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF VUPANORSEN PF07285557 IN STATINTREATED PARTICIPANTS WITH DYSLIPIDEMIA No dispute reported 06/30/2026 832866243
Principal investigator 1 PFIZER INC. $11,739.00 11/05/2021 Non-covered Recipient Entity
Accellacare of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832866253
Principal investigator 1 PFIZER INC. $728.38 10/30/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832603477
Principal investigator 1 PFIZER INC. $413.83 10/27/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832604705
Principal investigator 1 Kowa Research Institute, Inc. $2,478.60 10/26/2021 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 771715110
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $6,529.35 10/22/2021 Non-covered Recipient Entity
PMG RESEARCH INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851028691
Principal investigator 1 PFIZER INC. $3,488.40 10/22/2021 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832831203
Principal investigator 1 PFIZER INC. $728.38 10/16/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832605819
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,500.00 10/14/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851028061
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,000.00 10/14/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851028063
Principal investigator 1 PFIZER INC. $2,830.95 10/09/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832604231
Principal investigator 1 PFIZER INC. $762.75 10/08/2021 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832654679
Principal investigator 1 PFIZER INC. $3,950.10 10/08/2021 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832776597
Principal investigator 1 PFIZER INC. $1,000.00 10/08/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832885149
Principal investigator 1 PFIZER INC. $3,460.05 10/05/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832603895
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $22,275.60 09/27/2021 Non-covered Recipient Entity
PMG RESEARCH INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851027633
Principal investigator 1 PFIZER INC. $2,163.53 09/25/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832603083
Principal investigator 1 Kowa Research Institute, Inc. $3,582.90 09/24/2021 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 771714054
Principal investigator 1 PFIZER INC. $11,807.10 09/23/2021 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832703933
Principal investigator 1 PFIZER INC. $8,000.00 09/22/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 832654499
Principal investigator 1 PFIZER INC. $977.40 09/22/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF VUPANORSEN PF07285557 IN STATINTREATED PARTICIPANTS WITH DYSLIPIDEMIA No dispute reported 06/30/2026 832854919
Principal investigator 1 PFIZER INC. $73.92 09/22/2021 Non-covered Recipient Entity
PMG Research of Raleigh
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832866577
Principal investigator 1 PFIZER INC. $73.92 09/22/2021 Non-covered Recipient Entity
PMG Research of Raleigh
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832914219
Principal investigator 1 PFIZER INC. $4,701.54 09/21/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832603073
Principal investigator 1 PFIZER INC. $14,215.50 09/15/2021 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832654705
Principal investigator 1 PFIZER INC. $3,881.87 09/14/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832603865
Principal investigator 1 PFIZER INC. $7,533.82 09/08/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832604250
Principal investigator 1 PFIZER INC. $2,743.20 09/04/2021 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832751753
Principal investigator 1 PFIZER INC. $517.05 09/04/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF VUPANORSEN PF07285557 IN STATINTREATED PARTICIPANTS WITH DYSLIPIDEMIA No dispute reported 06/30/2026 832888575
Principal investigator 1 Allergan, Inc. $1,000.00 08/31/2021 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 789007395
Principal investigator 1 Allergan, Inc. $500.00 08/31/2021 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 789007397
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $10,012.05 08/31/2021 Non-covered Recipient Entity
PMG RESEARCH INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851027151
Principal investigator 1 PFIZER INC. $5,010.46 08/31/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832603102
Principal investigator 1 PFIZER INC. $6,210.00 08/27/2021 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832654666
Principal investigator 1 PFIZER INC. $8,699.70 08/24/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832605829
Principal investigator 1 Kowa Research Institute, Inc. $792.90 08/23/2021 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 771714052
Principal investigator 1 PFIZER INC. $136,802.25 08/21/2021 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832654477
Principal investigator 1 PFIZER INC. $7,627.50 08/21/2021 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832736751
Principal investigator 1 PFIZER INC. $977.40 08/21/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF VUPANORSEN PF07285557 IN STATINTREATED PARTICIPANTS WITH DYSLIPIDEMIA No dispute reported 06/30/2026 832817797
Principal investigator 1 PFIZER INC. $6,629.52 08/14/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832604695
Principal investigator 1 PFIZER INC. $4,832.48 08/07/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832600543
Principal investigator 1 PFIZER INC. $15,654.60 08/06/2021 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832694989
Principal investigator 1 PFIZER INC. $1,128.60 08/06/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF VUPANORSEN PF07285557 IN STATINTREATED PARTICIPANTS WITH DYSLIPIDEMIA No dispute reported 06/30/2026 832767743
Principal investigator 1 PFIZER INC. $1,241.49 08/03/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832603885
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $18,792.90 07/26/2021 Non-covered Recipient Entity
PMG RESEARCH INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851026393
Principal investigator 1 Kowa Research Institute, Inc. $2,097.00 07/26/2021 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 771714050
Principal investigator 1 PFIZER INC. $2,899.90 07/24/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832604685
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 07/20/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838424425
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 07/20/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838424433
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 07/20/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838424441
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 07/20/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838424449
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 07/20/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838424457
Principal investigator 1 PFIZER INC. $413.83 07/14/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832600177
Principal investigator 1 PFIZER INC. $10,500.00 07/09/2021 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832654489
Principal investigator 1 PFIZER INC. $13,651.20 07/09/2021 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832795149
Principal investigator 1 PFIZER INC. $611.55 07/09/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF VUPANORSEN PF07285557 IN STATINTREATED PARTICIPANTS WITH DYSLIPIDEMIA No dispute reported 06/30/2026 832904089
Principal investigator 1 PFIZER INC. $413.83 07/07/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832603487
Principal investigator 1 PFIZER INC. $390.00 07/01/2021 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832771367
Principal investigator 1 PFIZER INC. $10,255.00 07/01/2021 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832824265
Principal investigator 1 PFIZER INC. $300.00 07/01/2021 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832826103
Principal investigator 1 PFIZER INC. $2,250.00 07/01/2021 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832923789
Principal investigator 1 PFIZER INC. $413.83 06/30/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832603901
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $10,063.35 06/29/2021 Non-covered Recipient Entity
PMG RESEARCH INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851025487
Principal investigator 1 Kowa Research Institute, Inc. $693.00 06/24/2021 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 771711876
Principal investigator 1 PFIZER INC. $413.83 06/23/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832602617
Principal investigator 1 PFIZER INC. $611.55 06/23/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF VUPANORSEN PF07285557 IN STATINTREATED PARTICIPANTS WITH DYSLIPIDEMIA No dispute reported 06/30/2026 832703723
Principal investigator 1 PFIZER INC. $11,221.20 06/23/2021 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832863057
Principal investigator 1 PFIZER INC. $1,923.80 06/23/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832903587
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 06/22/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838420593
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 06/22/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838420601
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 06/22/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838420609
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 06/22/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838420617
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 06/22/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838420625
Principal investigator 1 PFIZER INC. $827.66 06/22/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832602597
Principal investigator 1 Allergan, Inc. $1,088.85 06/15/2021 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 789007393
Principal investigator 1 PFIZER INC. $413.83 06/09/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832603911
Principal investigator 1 PFIZER INC. $577.14 06/09/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832885353
Principal investigator 1 PFIZER INC. $22,005.00 06/05/2021 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832724373
Principal investigator 1 PFIZER INC. $2,679.75 06/05/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF VUPANORSEN PF07285557 IN STATINTREATED PARTICIPANTS WITH DYSLIPIDEMIA No dispute reported 06/30/2026 832759981
Principal investigator 1 PFIZER INC. $1,075.28 05/29/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832599663
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $13,440.60 05/27/2021 Non-covered Recipient Entity
PMG RESEARCH INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851024743
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $20,856.58 05/27/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851024895
Principal investigator 1 Kowa Research Institute, Inc. $1,874.70 05/25/2021 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 771711874
Principal investigator 1 PFIZER INC. $760.73 05/22/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832604241
Principal investigator 1 PFIZER INC. $7,854.30 05/21/2021 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832742605
Principal investigator 1 PFIZER INC. $728.38 05/08/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832603093
Principal investigator 1 PFIZER INC. $79.20 05/07/2021 Non-covered Recipient Entity
PMG Research of Raleigh
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832691631
Principal investigator 1 PFIZER INC. $79.20 05/07/2021 Non-covered Recipient Entity
PMG Research of Raleigh
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832735949
Principal investigator 1 PFIZER INC. $4,340.00 05/07/2021 Non-covered Recipient Entity
PMG Research of Raleigh
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832839699
Principal investigator 1 PFIZER INC. $7,854.30 05/07/2021 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832878261
Principal investigator 1 PFIZER INC. $629.10 05/01/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832599353
Principal investigator 1 Kowa Research Institute, Inc. $1,893.60 04/26/2021 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 771711872
Principal investigator 1 PFIZER INC. $2,571.39 04/24/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832605021
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 04/22/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838406377
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 04/22/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838406385
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 04/22/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838406391
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 04/22/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838406397
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 04/22/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838406405
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 04/22/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838406413
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 04/22/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838406421
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 04/22/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838406429
Principal investigator 1 PFIZER INC. $1,551.15 04/21/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF VUPANORSEN PF07285557 IN STATINTREATED PARTICIPANTS WITH DYSLIPIDEMIA No dispute reported 06/30/2026 832759971
Principal investigator 1 PFIZER INC. $7,979.70 04/17/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832600551
Principal investigator 1 PFIZER INC. $226.24 04/12/2021 Non-covered Recipient Entity
PMG Research of Raleigh
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832711639
Principal investigator 1 PFIZER INC. $13,864.17 04/10/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832603875
Principal investigator 1 PFIZER INC. $2,706.75 04/09/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF VUPANORSEN PF07285557 IN STATINTREATED PARTICIPANTS WITH DYSLIPIDEMIA No dispute reported 06/30/2026 832834485
Principal investigator 1 PFIZER INC. $8,194.28 04/03/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832602949
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $5,000.00 03/30/2021 Non-covered Recipient Entity
PMG RESEARCH INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851023773
Principal investigator 1 PFIZER INC. $16,465.20 03/27/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832602607
Principal investigator 1 PFIZER INC. $3,223.80 03/24/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF VUPANORSEN PF07285557 IN STATINTREATED PARTICIPANTS WITH DYSLIPIDEMIA No dispute reported 06/30/2026 832824275
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 03/23/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838401937
Principal investigator 1 Kowa Research Institute, Inc. $2,215.80 03/23/2021 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 771712870
Principal investigator 1 PFIZER INC. $14,802.74 03/20/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832602589
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,347.77 03/16/2021 Non-covered Recipient Entity
PMG Research Inc
Phase II study of BI456906 in Patients with T2DM O No dispute reported 06/30/2026 840492567
Principal investigator 1 PFIZER INC. $30,087.53 03/13/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832602941
Principal investigator 1 PFIZER INC. $12,789.17 03/06/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832605031
Principal investigator 1 Kowa Research Institute, Inc. $1,200.60 03/01/2021 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 771712868
Principal investigator 1 PFIZER INC. $26,521.58 02/27/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832603469
Principal investigator 1 PFIZER INC. $8,000.00 02/23/2021 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832692889
Principal investigator 1 PFIZER INC. $194,752.96 02/20/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832602579
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 02/19/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838393895
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 02/19/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838393903
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 02/19/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838393909
Principal investigator 1 PFIZER INC. $260.00 02/19/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832704891
Principal investigator 1 PFIZER INC. $1,875.00 02/19/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832736843
Principal investigator 1 PFIZER INC. $19,235.00 02/19/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832795159
Principal investigator 1 PFIZER INC. $250.00 02/19/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832840579
Principal investigator 1 PFIZER INC. $892.36 02/13/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832604715
Principal investigator 1 PFIZER INC. $1,687.67 02/06/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832602967
Principal investigator 1 PFIZER INC. $6,897.15 02/05/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832896793
Principal investigator 1 PFIZER INC. $827.66 01/30/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832604675
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,250.00 01/27/2021 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
MULTI-CENTER CROSS-SECTIONAL EPIDEMIOLOGICAL STUDY TO CHARACTERIZE THE PREVALENCE AND DISTRIBUTION OF LIPOPROTEIN(A) LEVELS AMONG PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 800637627
Principal investigator 1 Kowa Research Institute, Inc. $2,691.90 01/26/2021 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 771712866
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 01/25/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838388791
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 01/25/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838388798
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 01/25/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838388805
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 01/25/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838388813
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 01/25/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838388861
Principal investigator 1 PFIZER INC. $1,241.49 01/23/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832599683
Principal investigator 1 PFIZER INC. $1,241.49 01/16/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832605813
Principal investigator 1 Novartis Pharmaceuticals Corporation $197.89 01/15/2021 Non-covered Recipient Entity
ACCELLECARE
A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL ASSESSING THE IMPACT OF LIPOPROTEIN (A) LOWERING WITH TQJ230 ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 800619211
Principal investigator 1 Allergan, Inc. $1,014.60 01/14/2021 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 789007391
Principal investigator 1 PFIZER INC. $1,323.00 01/12/2021 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 832839691
Principal investigator 1 PFIZER INC. $8,000.00 01/12/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF VUPANORSEN PF07285557 IN STATINTREATED PARTICIPANTS WITH DYSLIPIDEMIA No dispute reported 06/30/2026 832851521
Principal investigator 1 PFIZER INC. $8,602.20 01/09/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832767835
Principal investigator 1 Ferring Pharmaceuticals AS $2,499.00 01/08/2021 Non-covered Recipient Entity
PMG RESEARCH INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 780072225
Principal investigator 1 PFIZER INC. $1,720.02 01/08/2021 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832605037
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,733.61 01/01/2021 Non-covered Recipient Entity
Pmg Research Of Raleigh LLC
Phase II study of BI456906 in Patients with T2DM O No dispute reported 06/30/2026 840491343